Exclusive Summary

• The patent has long expired with zero entry barriers, enabling rapid global market penetration in OTC and primary care sectors via distribution models.
• The 0.3g and 0.5g dosages accurately target the core demands for antipyresis, analgesia, and acute cardiovascular emergencies, serving billions of patients globally.
• Securely listed in the WHO Essential Medicines List and recommended by major clinical guidelines, it is an absolute first-line necessity for any pharmaceutical catalog.
• Supported by China's comprehensive upstream and downstream API supply chain, the product boasts absolute cost advantages and the capability for massive, stable deliveries.